Drug Profile


Alternative Names: 823093; GW 823093; GW823093C; Redona

Latest Information Update: 29 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antihyperglycaemics; Aromatic amino acids; Pyrrolidines; Small molecules
  • Mechanism of Action Dipeptidyl-peptidase and tripeptidyl-peptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 20 Apr 2015 GlaxoSmithKline withdraws a phase II/III trial in Type-2 diabetes mellitus in USA and Finland due to the cancellation of the trial (NCT00387972; EudraCT2006-002157-79)
  • 08 Nov 2006 Suspended - Phase-III for Type-2 diabetes mellitus in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top